Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spatial Multi-Omics for Predicting Efficacy of ADT + ARPIs in mHSPC
NCT07795177Phase 2Not yet recruiting
- Sponsor
- Anhui Medical University
- Start
- Oct 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
A Phase 2 trial of abiraterone, apalutamide, enzalutamide, rezvilutamide, darolutamide in prostate cancer (PCa), sponsored by Anhui Medical University. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
abirateroneapalutamideenzalutamiderezvilutamidedarolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07795177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07795177.